Brief introduction of Sinopharm Group Consistent Pharmaceutical Co., Ltd.

In 2004, it was transformed from a Shenzhen state-owned enterprise into a big family of China Pharmaceutical Group. Through capital operation and resource integration, the company's operating strength and performance have achieved leap-forward development. Sales revenue increased by more than 9 times compared with 2004, total profit increased by 20 times compared with 2004, and the average annual growth rate of main business income reached more than 20%. By the end of 20 1 1, the company's sales revenue has exceeded1500 million yuan.

The pharmaceutical industry controlled by Sinopharm integrates product research and development, production and marketing of raw materials and preparations, and its products mainly cover cephalosporins and respiratory system.

Medicine, digestive system medicine, cardiovascular and cerebrovascular medicine and anti-tumor drugs. Its wholly-owned enterprises Shenzhen Zhijun Pharmaceutical Co., Ltd., Sinopharm Holding Shenzhen Traditional Chinese Medicine Co., Ltd., Suzhou Zhijun Wanqing Pharmaceutical Co., Ltd. and Shenzhen Wan Le Pharmaceutical Co., Ltd. all belong to national high-tech enterprises. Cefuroxime, cefixime, cefoxitin, cefminox, cefoperazone and other key raw materials or preparations are in a leading position in the market segment, with sales of six single products exceeding 100 million yuan. Among them, Shenzhen Zhijun Pharmaceutical Co., Ltd. is the first domestic cephalosporin powder injection manufacturer whose independent products have passed the EU GMP certification, ranking among the top 50 pharmaceutical enterprises in China.

The pharmaceutical distribution business of Sinopharm Holdings ranks among the best in Guangdong and Guangxi provinces, and ranks among the top 20 pharmaceutical businesses in China. Its subsidiaries are located in Shenzhen, Guangzhou, Dongguan, Foshan, Zhanjiang, Meizhou, Zhaoqing, Huizhou, Nanning, Liuzhou, Jiangmen, Guilin, Yulin and Baise. Its business covers hospital pure sales, commercial deployment, rapid drug approval, terminal distribution and other formats, with a complete national commercial network and deep penetration into the southern terminal market. The unified distribution of Sinopharm strives to build an intelligent supply chain, integrating logistics, capital flow and information flow from manufacturers to end users, making information available everywhere and real-time business processing, fully meeting the needs of all parties and creating a brand-new distribution business model.